Epigenetic therapy worth pursuing in hormone receptor positive advanced breast cancer
Epigenetic therapy with histone deacetylase (HDAC) inhibitors is worth pursuing in hormone receptor positive advanced breast cancer, suggests a phase III trial reported today at the ESMO 2018 Congress in Munich.
Oct 22, 2018
0
1